Newsfeeds Archive - Page 3 of 64

4 minute read

Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare

May 29, 10:51 AM

Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest wealth transfer in history.

BMY

3 minute read

What the Options Market Tells Us About Johnson & Johnson

By Benzinga Insights

May 28, 1:16 PM

Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson (NYSE:JNJ), and it’s something market players shouldn’t…

JNJ

2 minute read

Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies

By Vandana Singh

May 23, 2:00 PM

U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq.

AZN

2 minute read

Johnson & Johnson’s Bankruptcy Tactics Are Fraudulent, Plaintiffs Accuse Company Of Defrauding Cancer Victims

By Vandana Singh

May 23, 11:26 AM

Cancer victims have filed a lawsuit against Johnson & Johnson, accusing the company of fraudulently using a shell company's bankruptcy to evade lawsuits. The plaintiffs claim the "Texas two-step" maneuver was designed to protect J&J's assets from litigation.

JNJ

4 minute read

Analyst Ratings

Expert Ratings For Johnson & Johnson

By Benzinga Insights

May 22, 11:00 AM

Johnson & Johnson (NYSE:JNJ) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints…

JNJ

3 minute read

Smart Money Is Betting Big In JNJ Options

By Benzinga Insights

May 21, 3:31 PM

Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson (NYSE:JNJ), and it’s something market players shouldn’t…

JNJ

4 minute read

Inquiry Into Johnson & Johnson’s Competitor Dynamics In Pharmaceuticals Industry

By Benzinga Insights

May 20, 11:00 AM

In today’s fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze…

JNJ

1 minute read

Johnson & Johnson Reports TREMFYA QUASAR Maintenance Study In UC Met Its Primary Endpoint And All Major Secondary Endpoints, Including Highly Statistically Significant Rates Of Endoscopic Remission

By Benzinga Newsdesk

May 20, 8:11 AM

Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative colitisa (UC)

JNJ